Shares of Repligen Co. (NASDAQ:RGEN) have earned a consensus broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and two have given a strong buy recommendation to the company.
Analysts have set a 12-month consensus price objective of $35.33 for the company and are forecasting that the company will post $0.13 EPS for the current quarter, according to Zacks. Zacks has also given Repligen an industry rank of 97 out of 265 based on the ratings given to its competitors.
RGEN has been the subject of several recent research reports. Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating in a research note on Thursday, January 26th. Piper Jaffray Companies raised Repligen from a “neutral” rating to an “overweight” rating and set a $3.57 price objective for the company in a research note on Monday, February 13th.
Repligen (NASDAQ:RGEN) traded down 2.09% during trading on Friday, hitting $35.09. 171,209 shares of the company were exchanged. The stock has a market capitalization of $1.19 billion, a PE ratio of 103.21 and a beta of 1.58. Repligen has a 1-year low of $21.11 and a 1-year high of $36.10. The firm’s 50 day moving average price is $33.97 and its 200-day moving average price is $31.62.
Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, February 22nd. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.01. Repligen had a return on equity of 10.16% and a net margin of 6.89%. The firm had revenue of $25.60 million for the quarter, compared to analyst estimates of $24.05 million. During the same quarter last year, the firm posted $0.07 EPS. The business’s revenue was up 19.6% on a year-over-year basis. Equities analysts predict that Repligen will post $0.55 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Repligen Co. (RGEN) Given Average Recommendation of “Buy” by Brokerages” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/04/21/repligen-co-rgen-receives-average-recommendation-of-buy-from-brokerages-updated.html.
In related news, Director Karen A. Dawes sold 2,521 shares of the stock in a transaction on Tuesday, March 21st. The stock was sold at an average price of $34.12, for a total value of $86,016.52. Following the completion of the transaction, the director now directly owns 95,764 shares of the company’s stock, valued at approximately $3,267,467.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Howard Benjamin sold 12,216 shares of the stock in a transaction on Monday, March 20th. The shares were sold at an average price of $34.62, for a total value of $422,917.92. Following the completion of the transaction, the vice president now directly owns 36,124 shares of the company’s stock, valued at $1,250,612.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,646 shares of company stock valued at $714,898. 2.30% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue increased its stake in shares of Repligen by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock worth $131,000 after buying an additional 80 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Repligen by 3.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 6,388 shares of the biotechnology company’s stock worth $197,000 after buying an additional 223 shares during the period. Municipal Employees Retirement System of Michigan increased its stake in shares of Repligen by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 7,460 shares of the biotechnology company’s stock worth $225,000 after buying an additional 120 shares during the period. Capstone Investment Advisors LLC bought a new stake in shares of Repligen during the fourth quarter worth about $243,000. Finally, Aperio Group LLC increased its stake in shares of Repligen by 1.9% in the third quarter. Aperio Group LLC now owns 8,200 shares of the biotechnology company’s stock worth $248,000 after buying an additional 151 shares during the period. 94.35% of the stock is owned by institutional investors and hedge funds.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with MarketBeat.com's FREE daily email newsletter.